Navidea Biopharmaceuticals Inc (NYSE MKT LLC:NAVB)
| 2.64 Data as of 9:30am ET |  -0.02 / -0.75%Today’s Change | 2.14 Today|||52-Week Range 4.77 | -6.71% Year-to-Date |
Latest NAVB News | Press Releases
No recent news for Navidea Biopharmaceuticals Inc.
Today’s Trading
| Previous close | 2.66 |
| Today’s open | 2.64 |
| Day’s range | 2.64 - 2.64 |
| Volume | 13,626 |
| Average volume (3 months) | 870,318 |
| Market cap | $318.1M |
| Dividend yield | -- |
Data as of 9:30am ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -96.53% |
| Earnings growth (this year) | +11.49% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -86.83% |
| P/E ratio | NM |
| Price/Sales | 3,560.41 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XOMAXOMA Corp | -0.01 | -0.39% |
| OMTHOmthera Pharmaceutic... | 0.00 | 0.00% |
| RCPTReceptos Inc | 0.00 | 0.00% |
| ENTAEnanta Pharmaceutica... | 0.00 | 0.00% |
Data as of 9:47am ET, 06/19/2013
Financials
| Next reporting date | August 5, 2013 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $78.7K |
| Annual profit (last year) | -$29.2M |
| Net profit margin | -37,030.66% |
Profile
Sector Health Technology |
Industry Medical Specialties |
Chief Executive Officer Mark Jerome Pykett, PhD, MBA |
President & Chief Business Officer Thomas H. Tulip, PhD |
Corporate headquarters Dublin, Ohio |
Forecasts
